1. Home
  2. NAMS vs TDC Comparison

NAMS vs TDC Comparison

Compare NAMS & TDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • TDC
  • Stock Information
  • Founded
  • NAMS 2019
  • TDC 1979
  • Country
  • NAMS Netherlands
  • TDC United States
  • Employees
  • NAMS N/A
  • TDC N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • TDC Computer Software: Prepackaged Software
  • Sector
  • NAMS Health Care
  • TDC Technology
  • Exchange
  • NAMS Nasdaq
  • TDC Nasdaq
  • Market Cap
  • NAMS 2.2B
  • TDC 2.1B
  • IPO Year
  • NAMS N/A
  • TDC 2007
  • Fundamental
  • Price
  • NAMS $18.11
  • TDC $21.95
  • Analyst Decision
  • NAMS Strong Buy
  • TDC Hold
  • Analyst Count
  • NAMS 6
  • TDC 9
  • Target Price
  • NAMS $42.83
  • TDC $30.00
  • AVG Volume (30 Days)
  • NAMS 694.5K
  • TDC 1.1M
  • Earning Date
  • NAMS 05-08-2025
  • TDC 05-06-2025
  • Dividend Yield
  • NAMS N/A
  • TDC N/A
  • EPS Growth
  • NAMS N/A
  • TDC 241.18
  • EPS
  • NAMS N/A
  • TDC 1.41
  • Revenue
  • NAMS $47,140,000.00
  • TDC $1,703,000,000.00
  • Revenue This Year
  • NAMS N/A
  • TDC N/A
  • Revenue Next Year
  • NAMS N/A
  • TDC $0.97
  • P/E Ratio
  • NAMS N/A
  • TDC $15.55
  • Revenue Growth
  • NAMS 586.97
  • TDC N/A
  • 52 Week Low
  • NAMS $14.06
  • TDC $18.43
  • 52 Week High
  • NAMS $27.29
  • TDC $35.60
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 47.80
  • TDC 47.91
  • Support Level
  • NAMS $16.79
  • TDC $21.42
  • Resistance Level
  • NAMS $19.58
  • TDC $22.11
  • Average True Range (ATR)
  • NAMS 0.94
  • TDC 0.43
  • MACD
  • NAMS -0.12
  • TDC -0.11
  • Stochastic Oscillator
  • NAMS 47.07
  • TDC 23.45

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About TDC Teradata Corporation

Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.

Share on Social Networks: